Emerging Biopharmaceutical Markets to Exceed US$ 13.6 Billion by 2015

June 07, 2011
Top Quote IMARC Group, one of the world's leading research and advisory firms, finds that the sales of Biopharmaceuticals in Emerging markets will nearly triple its size from US$ 5.3 Billion in 2010 to US$ 13.5 Billion in 2015. End Quote
  • (1888PressRelease) June 07, 2011 - IMARC Group, one of the world's leading research and advisory firms, finds in its new report "Global Biopharmaceutical Market Report & Forecast 2010-2015" that driven by a huge patient pool, rapid economic growth and improving intellectual property rights, the sales of biopharmaceuticals in the seven emerging markets- Russia, China, Turkey, Mexico, South Korea, India and Brazil will nearly triple from the current US$ 5.3 Billion to more than US$ 13.6 billion by 2015.

    As per the research findings, the treatment costs associated with biopharmaceuticals are extremely high and at times can exceed hundreds of thousands of dollars a year. Since most of the healthcare costs in the emerging markets are paid out-of-pocket, most patients cannot afford these treatments. However, the seven emerging markets taken together account for more than three billion people, representing more than 45% of the total Global population. So even if a small percentage of patients are able to afford these drugs, it still represents a huge market potential. Moreover, the GDPs of emerging markets have witnessed strong growth during the last few years, and this is likely to continue in the coming years as well. This is expected to create a huge middle class that can afford innovative treatments.

    The report also suggests that despite the huge opportunity, these markets will not be easy for western manufacturers to penetrate. A major challenge for manufacturers entering these markets is the fact that emerging markets are more complex and different from the developed markets as well as from each other. A strategy that will work in Turkey will not work well in India or China. Manufacturers will have to devise strategies, customized as per the requirements of the individual markets.

    IMARC's new report "Global Biopharmaceutical Market Report 2010-2015" gives a deep insight into the global biopharmaceutical market. The research study serves as an analytical as well as a statistical tool to understand the strengths, weaknesses, opportunities, threats, market trends, geographical structure, therapeutic structure, competitive structure and the outlook of the global biopharmaceutical market till 2015. This report can serve as an excellent guide for investors, researchers, consultants, marketing strategists, and all those who are planning to foray into the global biopharmaceutical market in some form or the other.

    Table of Contents

    1. Market Definitions & Research Methodology
    2. Analyst Briefing
    3. Introduction to Biopharmaceuticals
    4. Global Biopharmaceutical Market: Industry Analysis
    4.1 Strengths
    4.1.1 High Efficacy and Target Oriented Attack
    4.1.2 Strong Potential to Achieve Blockbuster Status
    4.1.3 Limited Generic Threat
    4.1.4 Approval Success Rates are Higher than Small Molecule Drugs
    4.2 Weaknesses
    4.2.1 Inconvenient Drug Delivery Coupled with Short Half Lives
    4.2.2 Second Line of Therapy
    4.2.3 Huge Cost of Therapy
    4.2.4 High Incidence of Unfavorable Side Effects
    4.3 Opportunities
    4.3.1 Diseases with High Unmet Needs
    4.3.2 Expanding the Patient Pool by Approval into Additional Indications
    4.3.3 Emerging Markets
    4.3.4 Increasing New Approvals and a Strong Pipeline
    4.4 Threats
    4.4.1 Biopharmaceutical Drug Development is a Very Risky Venture
    4.4.2 Biosimilars
    4.4.3 Limited and Conditional Reimbursement
    4.4.4 Uncertainties in the Economic Environment
    5. Global Biopharmaceutical Market: Industry Performance
    5.1 Market Performance & Forecast
    5.1.1 Current Performance (2005-2009)
    5.1.2 Market Forecasts (2010-2015)
    5.2 Market Segmentation by Region
    5.2.1 Current Performance (2005-2009)
    5.2.2 Market Forecasts (2010-2015)
    5.3 Market Segmentation by Indication
    5.4 Market Segmentation by Class
    5.4.1 Recombinant Proteins
    5.4.1.1 Current Performance (2005-2009)
    5.4.1.2 Market Forecasts (2010-2015)
    5.4.2 Monoclonal Antibodies
    5.4.2.1 Current Performance (2005-2009)
    5.4.2.2 Market Forecast (2010-2015)
    5.4.3 Purified Proteins
    5.4.3.1 Current Performance (2005-2009)
    5.4.3.2 Market Forecast (2010-2015)
    5.5 Competitive Landscape
    5.5.1 Top Biopharmaceutical Players
    5.5.2 Top Biopharmaceutical Drugs
    6. North America
    6.1 US
    6.1.1 Market Performance (2005-2009)
    6.1.2 Market Segmentation by Class
    6.1.2.1 Recombinant Proteins
    6.1.2.2 Monoclonal Antibodies
    6.1.2.3 Purified Proteins
    6.1.3 Performance of Top Players
    6.1.4 Market Forecasts (2010-2015)
    6.2 Canada
    6.2.1 Market Performance (2005-2009)
    6.2.2 Market Segmentation by Class
    6.2.2.1 Recombinant Proteins
    6.2.2.2 Monoclonal Antibodies
    6.2.3 Performance of Top Players
    6.2.4 Market Forecasts (2010-2015)
    7. Latin America
    7.1 Mexico
    7.1.1 Market Performance (2005-2009)
    7.1.2 Market Segmentation by Class
    7.1.2.1 Recombinant Proteins
    7.1.2.2 Monoclonal Antibodies
    7.1.2.3 Purified Proteins
    7.1.3 Performance of Top Players
    7.1.4 Market Forecasts (2010-2015)
    7.2 Brazil
    7.2.1 Market Performance (2005-2009)
    7.2.2 Market Segmentation by Class
    7.2.2.1 Recombinant Proteins
    7.2.2.2 Monoclonal Antibodies
    7.2.2.3 Purified Proteins
    7.2.3 Performance of Top Players
    7.2.4 Market Forecasts (2010-2015)
    7.3 Argentina
    7.3.1 Market Performance (2005-2009)
    7.3.2 Market Segmentation by Class
    7.3.2.1 Recombinant Proteins
    7.3.2.2 Monoclonal Antibodies
    7.3.2.3 Purified Proteins
    7.3.3 Performance of Top Players
    7.3.4 Market Forecasts (2010-2015)
    8. Europe
    8.1 Germany
    8.1.1 Market Performance (2005-2009)
    8.1.2 Market Segmentation by Class
    8.1.2.1 Recombinant Proteins
    8.1.2.2 Monoclonal Antibodies
    8.1.2.3 Purified Proteins
    8.1.3 Performance of Top Players
    8.1.4 Market Forecasts (2010-2015)
    8.2 France
    8.2.1 Market Performance (2005-2009)
    8.2.2 Market Segmentation by Class
    8.2.2.1 Recombinant Proteins
    8.2.2.2 Monoclonal Antibodies
    8.2.2.3 Purified Proteins
    8.2.3 Performance of Top Players
    8.2.4 Market Forecasts (2010-2015)
    8.3 Italy
    8.3.1 Market Performance (2005-2009)
    8.3.2 Market Segmentation by Class
    8.3.2.1 Recombinant Proteins
    8.3.2.2 Monoclonal Antibodies
    8.3.2.3 Purified Proteins
    8.3.3 Performance of Top Players
    8.3.4 Market Forecasts (2010-2015)
    8.4 Spain
    8.4.1 Market Performance (2005-2009)
    8.4.2 Market Segmentation by Class
    8.4.2.1 Recombinant Proteins
    8.4.2.2 Monoclonal Antibodies
    8.4.2.3 Purified Proteins
    8.4.3 Performance of Top Players
    8.4.4 Market Forecasts (2010-2015)
    8.5 UK
    8.5.1 Market Performance (2005-2009)
    8.5.2 Market Segmentation by Class
    8.5.2.1 Recombinant Proteins
    8.5.2.2 Monoclonal Antibodies
    8.5.2.3 Purified Proteins
    8.5.3 Performance of Top Players
    8.5.4 Market Forecasts (2010-2015)
    8.6 Russia
    8.6.1 Market Performance (2005-2009)
    8.6.2 Market Segmentation by Class
    8.6.2.1 Recombinant Proteins
    8.6.2.2 Monoclonal Antibodies
    8.6.2.3 Purified Proteins
    8.6.3 Performance of Top Players
    8.6.4 Market Forecasts (2010-2015)
    8.7 Turkey
    8.7.1 Market Performance (2005-2009)
    8.7.2 Market Segmentation by Class
    8.7.2.1 Recombinant Proteins
    8.7.2.2 Monoclonal Antibodies
    8.7.2.3 Purified Proteins
    8.7.3 Performance of Top Players
    8.7.4 Market Forecasts (2010-2015)
    9. Asia Pacific
    9.1 Japan
    9.1.1 Market Performance (2005-2009)
    9.1.2 Market Segmentation by Class
    9.1.2.1 Recombinant Proteins
    9.1.2.2 Monoclonal Antibodies
    9.1.2.3 Purified Proteins
    9.1.3 Performance of Top Players
    9.1.4 Market Forecasts (2010-2015)
    9.2 China
    9.2.1 Market Performance (2005-2009)
    9.2.2 Market Segmentation by Class
    9.2.2.1 Recombinant Proteins
    9.2.2.2 Monoclonal Antibodies
    9.2.2.3 Purified Proteins
    9.2.3 Performance of Top Players
    9.2.4 Market Forecasts (2010-2015)
    9.3 Australia
    9.3.1 Market Performance (2005-2009)
    9.3.2 Market Segmentation by Class
    9.3.2.1 Recombinant Proteins
    9.3.2.2 Monoclonal Antibodies
    9.3.2.3 Purified Proteins
    9.3.3 Performance of Top Players
    9.3.4 Market Forecasts (2010-2015)
    9.4 South Korea
    9.4.1 Market Performance (2005-2009)
    9.4.2 Market Segmentation by Class
    9.4.2.1 Recombinant Proteins
    9.4.2.2 Monoclonal Antibodies
    9.4.2.3 Purified Proteins
    9.4.3 Performance of Top Players
    9.4.4 Market Forecasts (2010-2015)
    9.5 India
    9.5.1 Market Performance (2005-2009)
    9.5.2 Market Segmentation by Class
    9.5.2.1 Recombinant Proteins
    9.5.2.2 Monoclonal Antibodies
    9.5.2.3 Purified Proteins
    9.5.3 Performance of Top Players
    9.5.4 Market Forecasts (2010-2015)
    9.6 Indonesia
    9.6.1 Market Performance (2005-2009)
    9.6.2 Market Segmentation by Class
    9.6.2.1 Recombinant Proteins
    9.6.2.2 Monoclonal Antibodies
    9.6.2.3 Purified Proteins
    9.6.3 Performance of Top Players
    9.6.4 Market Forecasts (2010-2015)

    To buy the complete report or to get a free sample:

    Call: +91-120-425-6531 (Asia), +44-844-774-9660 (Europe), +1-631-791-1145 (America)

    email: sales ( @ ) imarcgroup dot com

    ###
space
space
  • FB Icon Twitter Icon In-Icon
Contact Information
  • Krishna Sharma
  • Imarc Group
  • 21/601 Eastend Apartment Mayur Vihar Phase-1 Extention Delhi-110096, India
  • 201301
  • Voice: 91-120-4256531
  • Visit our Site
Over Satisfied Users & Approved Press Releases
© Copyright 2005-2024, 1888 Press Release. All Rights Reserved